CUE Cue Biopharma Inc

Price (delayed)

$10.88

Market cap

$341.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.49

Enterprise value

$271.86M

Highlights
The EPS is up by 7% YoY and by 4.5% QoQ
The company's equity has surged by 54% YoY but it fell by 12% QoQ
CUE's debt is up by 29% year-on-year but it is down by 15% since the previous quarter
The net income has contracted by 16% YoY

Key stats

What are the main financial stats of CUE
Market
Shares outstanding
31.41M
Market cap
$341.77M
Enterprise value
$271.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.76
Price to sales (P/S)
86.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
71.41
Earnings
Revenue
$3.81M
EBIT
-$44.27M
EBITDA
-$44.15M
Free cash flow
-$34.59M
Per share
EPS
-$1.49
Free cash flow per share
-$1.14
Book value per share
$2.29
Revenue per share
$0.13
TBVPS
$2.92
Balance sheet
Total assets
$88.72M
Total liabilities
$19.05M
Debt
$6.07M
Equity
$69.67M
Working capital
$60.77M
Liquidity
Debt to equity
0.09
Current ratio
4.65
Quick ratio
4.65
Net debt/EBITDA
1.58
Margins
EBITDA margin
-1,159.6%
Gross margin
100%
Net margin
-1,168.1%
Operating margin
-1,170.5%
Efficiency
Return on assets
-44.9%
Return on equity
-56.2%
Return on invested capital
-239.8%
Return on capital employed
-61.4%
Return on sales
-1,162.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CUE stock price

How has the Cue Biopharma stock price performed over time
Intraday
5.12%
1 week
2.35%
1 month
-8.88%
1 year
-46.9%
YTD
-13.03%
QTD
-6.61%

Financial performance

How have Cue Biopharma's revenue and profit performed over time
Revenue
$3.81M
Gross profit
$3.81M
Operating income
-$44.57M
Net income
-$44.47M
Gross margin
100%
Net margin
-1,168.1%
CUE's net margin is down by 22% year-on-year but it is up by 18% since the previous quarter
Cue Biopharma's operating margin has decreased by 22% YoY but it has increased by 18% from the previous quarter
The gross profit is up by 21% since the previous quarter but it is down by 4.5% year-on-year
CUE's revenue is up by 21% since the previous quarter but it is down by 4.5% year-on-year

Growth

What is Cue Biopharma's growth rate over time

Valuation

What is Cue Biopharma stock price valuation
P/E
N/A
P/B
4.76
P/S
86.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
71.41
The EPS is up by 7% YoY and by 4.5% QoQ
The company's equity has surged by 54% YoY but it fell by 12% QoQ
The P/B is 25% below the last 4 quarters average of 6.0
The price to sales (P/S) is 34% lower than the last 4 quarters average of 125.9
CUE's revenue is up by 21% since the previous quarter but it is down by 4.5% year-on-year

Efficiency

How efficient is Cue Biopharma business performance
Cue Biopharma's return on equity has increased by 46% YoY and by 8% QoQ
The ROA has grown by 36% YoY and by 8% from the previous quarter
The ROIC has decreased by 33% QoQ and by 6% YoY
The ROS is down by 23% YoY but it is up by 18% QoQ

Dividends

What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CUE.

Financial health

How did Cue Biopharma financials performed over time
The total assets is up by 46% year-on-year but it has declined by 11% since the previous quarter
Cue Biopharma's total liabilities has increased by 24% YoY but it has decreased by 8% from the previous quarter
CUE's debt is 91% smaller than its equity
The company's equity has surged by 54% YoY but it fell by 12% QoQ
CUE's debt is up by 29% year-on-year but it is down by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.